AVEO Pharmaceuticals (NASDAQ:AVEO) Sees Large Volume Increase After Earnings Beat

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) saw an uptick in trading volume on Wednesday following a stronger than expected earnings report. 196,654 shares traded hands during trading, a decline of 95% from the previous session’s volume of 4,142,819 shares.The stock last traded at $0.63 and had previously closed at $0.56.

The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.09. AVEO Pharmaceuticals had a negative return on equity of 50.69% and a negative net margin of 46.69%. The business had revenue of $25.72 million for the quarter.

A number of brokerages recently issued reports on AVEO. ValuEngine cut AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and issued a $1.75 price objective on shares of AVEO Pharmaceuticals in a research note on Tuesday, October 1st. Finally, Piper Jaffray Companies lowered their price objective on AVEO Pharmaceuticals from $4.00 to $2.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $1.92.

A number of institutional investors have recently made changes to their positions in the stock. Anson Funds Management LP bought a new stake in AVEO Pharmaceuticals in the 2nd quarter valued at about $33,000. OZ Management LP purchased a new position in AVEO Pharmaceuticals during the 2nd quarter valued at about $244,000. Jane Street Group LLC purchased a new position in AVEO Pharmaceuticals during the 2nd quarter valued at about $98,000. Morgan Stanley grew its holdings in AVEO Pharmaceuticals by 265.4% during the 2nd quarter. Morgan Stanley now owns 399,742 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 290,354 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new position in AVEO Pharmaceuticals during the 2nd quarter valued at about $321,000. Institutional investors and hedge funds own 29.56% of the company’s stock.

The company has a current ratio of 2.21, a quick ratio of 2.21 and a debt-to-equity ratio of 6.84. The firm has a market cap of $82.78 million, a PE ratio of -3.37 and a beta of 0.75. The stock has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $0.76.

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Recommended Story: Stock Split

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.